ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

Evaluation of ATG5 as Aserum Marker of Autophgy in Psoriasis Vulgaris Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05279638

Enrollment

Registered

2022-03-15

Start date

2022-02-01

Completion date

2024-01-01

Last updated

2022-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autophagy, Psoriasis Vulgaris

Keywords

serum marker, ATG5

Brief summary

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.

Interventions

DIAGNOSTIC_TESTserum ATG5

This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

Psoriasis vulgaris of both sex, age 18-55 years

Exclusion criteria

i. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months

Design outcomes

Primary

Measure	Time frame	Description
serum level of ATG5 in psoriatic patients	Within 6 months	evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA

Countries

Egypt

Contacts

Primary ContactAyatallah Hamdi Abdelrahmim

ayatallah_hamdy_post@med.sohag.edu.eg01005482447

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026